...A. And then with over 200,000 patients across other indications, including our ongoing Phase III program in non-infectious uveitis, and our proof-of-concept study ongoing in cutaneous sarcoidosis. B. Brepocitinib is the first dual selective TYK2/JAK1 inhibitor, the first-in-class of those. C. And brepocitinib finally is designed to impact both TYK2 and JAK1, which should give us potentially very robust efficacy across highly morbid heterogenous autoimmune disease. D. And the TYK2 is also responsible for interferon alpha and beta and IL-10 as well as IL-12 and IL-23. E. First of all, brepocitinib has been an incredible molecule in clinical development thus far. F. We have seven positive Phase II studies across a wide range of doses, many hundreds of patients....
